159 related articles for article (PubMed ID: 30052325)
21. Electrocardiographic Characterization of Ramucirumab on the Corrected QT Interval in a Phase II Study of Patients With Advanced Solid Tumors.
Olszanski AJ; Smith DC; Camacho LH; Thompson J; Ramalingam SS; Harvey RD; Campos L; Ferry D; Tang S; Gao L; Safran H
Oncologist; 2016 Apr; 21(4):402-3. PubMed ID: 26984445
[TBL] [Abstract][Full Text] [Related]
22. Application of a probabilistic method for the determination of drug-induced QT prolongation in telemetered cynomolgus monkeys: effects of moxifloxacin.
Holzgrefe HH; Cavero I; Buchanan LV; Gill MW; Durham SK
J Pharmacol Toxicol Methods; 2007; 55(3):227-37. PubMed ID: 17097307
[TBL] [Abstract][Full Text] [Related]
23. Sensitivity of common marmosets to detect drug-induced QT interval prolongation: moxifloxacin case study.
Komatsu R; Honda M; Holzgrefe HH; Kubo J; Yamada Y; Isobe T; Kimura K; Itoh T; Tamaoki N; Tabo M
J Pharmacol Toxicol Methods; 2010; 61(3):271-6. PubMed ID: 20097298
[TBL] [Abstract][Full Text] [Related]
24. Is a thorough QTc study necessary? The role of modeling and simulation in evaluating the QTc prolongation potential of drugs.
Rohatagi S; Carrothers TJ; Kuwabara-Wagg J; Khariton T
J Clin Pharmacol; 2009 Nov; 49(11):1284-96. PubMed ID: 19734373
[TBL] [Abstract][Full Text] [Related]
25. Randomized, placebo-controlled study to assess the impact on QT/QTc interval of supratherapeutic doses of ceftazidime-avibactam or ceftaroline fosamil-avibactam.
Das S; Armstrong J; Mathews D; Li J; Edeki T
J Clin Pharmacol; 2014 Mar; 54(3):331-40. PubMed ID: 24150927
[TBL] [Abstract][Full Text] [Related]
26. Problems of heart rate correction in assessment of drug-induced QT interval prolongation.
Malik M
J Cardiovasc Electrophysiol; 2001 Apr; 12(4):411-20. PubMed ID: 11332559
[TBL] [Abstract][Full Text] [Related]
27. Four-Way Crossover Phase 1 Thorough QT Study to Assess Cardiac Safety of Domperidone and Consideration for Design and Conduct of QT/QTc Study in China.
Wang F; Nie J; Yang L; Yang Z; Xu L; Wang L; Liao H; Li M; Wang P; Li G; Li H
Clin Pharmacol Drug Dev; 2022 Jun; 11(6):734-743. PubMed ID: 35157791
[TBL] [Abstract][Full Text] [Related]
28. Importance of QT/RR hysteresis correction in studies of drug-induced QTc interval changes.
Malik M; Garnett C; Hnatkova K; Johannesen L; Vicente J; Stockbridge N
J Pharmacokinet Pharmacodyn; 2018 Jun; 45(3):491-503. PubMed ID: 29651591
[TBL] [Abstract][Full Text] [Related]
29. Vigabatrin Lacks Proarrhythmic Potential: Results from a Thorough QT/QTc Study in Healthy Volunteers.
Tolbert D; Reid S; Harris S; Bekersky I
Clin Ther; 2017 Aug; 39(8):1639-1648. PubMed ID: 28668627
[TBL] [Abstract][Full Text] [Related]
30. Virtual Thorough QT (TQT) Trial-Extrapolation of In Vitro Cardiac Safety Data to In Vivo Situation Using Multi-Scale Physiologically Based Ventricular Cell-wall Model Exemplified with Tolterodine and Fesoterodine.
Patel N; Wisniowska B; Polak S
AAPS J; 2018 Jul; 20(5):83. PubMed ID: 29995258
[TBL] [Abstract][Full Text] [Related]
31. Loxapine delivered as a thermally generated aerosol does not prolong QTc in a thorough QT/QTc study in healthy subjects.
Spyker DA; Voloshko P; Heyman ER; Cassella JV
J Clin Pharmacol; 2014 Jun; 54(6):665-74. PubMed ID: 24375070
[TBL] [Abstract][Full Text] [Related]
32. Phase 1 Study to Evaluate the Effect of the Investigational Anticancer Agent Sapanisertib on the QTc Interval in Patients With Advanced Solid Tumors.
Patel C; Goel S; Patel MR; Rangachari L; Wilbur JD; Shou Y; Venkatakrishnan K; Lockhart AC
Clin Pharmacol Drug Dev; 2020 Oct; 9(7):876-888. PubMed ID: 32488989
[TBL] [Abstract][Full Text] [Related]
33. Assessment of Azeliragon QTc Liability Through Integrated, Model-Based Concentration QTc Analysis.
Burstein AH; Brantley SJ; Dunn I; Altstiel LD; Schmith V
Clin Pharmacol Drug Dev; 2019 May; 8(4):426-435. PubMed ID: 30934161
[TBL] [Abstract][Full Text] [Related]
34. Effect of pomaglumetad methionil on the QT interval in subjects with schizophrenia.
Zhang W; Mitchell MI; Knadler MP; Long A; Witcher J; Walling D; Annes W; Ayan-Oshodi M
Int J Clin Pharmacol Ther; 2015 Jun; 53(6):462-70. PubMed ID: 25881753
[TBL] [Abstract][Full Text] [Related]
35. A thorough QT/QTc study of the effect of fasiglifam, a GPR40 agonist, on cardiac repolarization in healthy adults.
Lee RD; Nudurupati S; Marcinak J; Viswanathan P
Clin Pharmacol Drug Dev; 2015; 4(3):175-83. PubMed ID: 27140797
[TBL] [Abstract][Full Text] [Related]
36. Potential strategy for assessing QT/QTc interval for drugs that produce rapid changes in heart rate: Electrocardiographic assessment of the effects of intravenous remimazolam on cardiac repolarization.
Kleiman RB; Darpo B; Thorn M; Stoehr T; Schippers F
Br J Clin Pharmacol; 2020 Aug; 86(8):1600-1609. PubMed ID: 32144789
[TBL] [Abstract][Full Text] [Related]
37. Daily dosing of vismodegib to steady state does not prolong the QTc interval in healthy volunteers.
Graham RA; Chang I; Jin JY; Wang B; Dufek MB; Ayache JA; Ezzet F; Zerivitz K; Low JA; Dresser MJ
J Cardiovasc Pharmacol; 2013 Jan; 61(1):83-9. PubMed ID: 23107871
[TBL] [Abstract][Full Text] [Related]
38. The imprecision in heart rate correction may lead to artificial observations of drug induced QT interval changes.
Malik M
Pacing Clin Electrophysiol; 2002 Feb; 25(2):209-16. PubMed ID: 11915990
[TBL] [Abstract][Full Text] [Related]
39. Cardiac repolarization with Gabapentin enacarbil in a randomized, double-blind, placebo- and active-controlled, crossover thorough QT/QTc study in healthy adults.
Davy M; Upward J; Arumugham T; Twomey C; Chen C; Stier B
Clin Ther; 2013 Dec; 35(12):1964-74. PubMed ID: 24290737
[TBL] [Abstract][Full Text] [Related]
40. Effects of Therapeutic and Supratherapeutic Doses of Siponimod (BAF312) on Cardiac Repolarization in Healthy Subjects.
Shakeri-Nejad K; Aslanis V; Veldandi UK; Mooney L; Pezous N; Brendani B; Juan A; Allison M; Perry R; Legangneux E
Clin Ther; 2015 Nov; 37(11):2489-2505.e2. PubMed ID: 26519230
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
